Expand CSTL Menu
CSTL MENU

CSTL Latest Press Releases

-- September 28, 2026 --

New Study Shows That TissueCypher Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus PRNewswire 7:00 AM

-- September 24, 2026 --

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx PRNewswire 4:30 PM

-- September 22, 2026 --

Castle Biosciences to Open New Laboratory Facility in Scottsdale PRNewswire 7:00 AM

-- September 15, 2026 --

New Decision Modeling Study Demonstrates TissueCypher Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus PRNewswire 7:01 AM

-- September 9, 2026 --

JAAD Publication Shows Improved Performance of DecisionDx-SCC PRNewswire 4:30 PM

-- September 8, 2026 --

SciBase receives additional order from Castle Biosciences, advancing the collaboration PRNewswire 9:32 AM

-- August 20, 2026 --

Castle Biosciences to Participate in Upcoming Investor Conferences PRNewswire 7:00 AM

-- August 17, 2026 --

Castle Biosciences Approved for Dual Listing on Nasdaq Texas PRNewswire 7:00 AM

-- July 30, 2026 --

Castle Biosciences Reports Second Quarter 2026 Results PRNewswire 4:05 PM

-- July 22, 2026 --

Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference PRNewswire 7:00 AM

-- July 14, 2026 --

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test PRNewswire 4:30 PM

-- July 9, 2026 --

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PRNewswire 7:00 AM

-- June 25, 2026 --

DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PRNewswire 4:30 PM

-- June 23, 2026 --

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal PRNewswire 7:01 AM

-- June 19, 2026 --

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 7:00 AM

-- June 16, 2026 --

Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus PRNewswire 7:00 AM

-- May 13, 2026 --

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference PRNewswire 7:00 AM

-- May 12, 2026 --

Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation PRNewswire 7:00 AM

-- May 5, 2026 --

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month PRNewswire 7:00 AM

-- May 4, 2026 --

New Data at DDW 2026 Show TissueCypher Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus PRNewswire 7:00 AM
Market Data Delayed 15 Minutes